| Bioactivity | SR121566A is a novel non-peptide Glycoprotein IIb/IIIa (GP IIb-IIIa) antagonist, which can inhibit ADP-, arachidonic acid- and collagen-induced human platelet aggregation with IC50s of 46±7.5, 56±6 and 42±3 nM, respectively. |
| Target | GP IIb-IIIa |
| In Vivo | SR121566A leads to dose-dependent increases in TTO, a statistically significant increase being observed at the doses of 0.3 mg/kg (473%) and 30 mg/kg (771%), respectively[2]. |
| Name | SR121566A |
| CAS | 180144-61-0 |
| Formula | C20H25N5O4S |
| Molar Mass | 431.51 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Herault JP, et al. Effect of SR121566A, a potent GP IIb-IIIa antagonist on platelet-mediated thrombin generation in vitro and in vivo. Thromb Haemost. 1998 Feb;79(2):383-8. [2]. Lorrain J, et al. Effects of SanOrg123781A, a synthetic hexadecasaccharide, in a mouse model of electrically induced carotid artery injury: synergism with the antiplatelet agent clopidogrel. J Pharmacol Exp Ther. 2004 Apr;309(1):235-40. |
SR121566A
CAS: 180144-61-0 F: C20H25N5O4S W: 431.51
SR121566A is a novel non-peptide Glycoprotein IIb/IIIa (GP IIb-IIIa) antagonist, which can inhibit ADP-, arachidonic aci
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.